Clinical trials: Advanced, open to volunteers
Advanced Solid Tumor
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal…
- Trial name
- NCT07408258
- Testing
- ONC-783
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- OncoC4, Inc.
Solid Tumors Harboring a TP53 Y220C Mutation
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
- Trial name
- NCT06908434
- Testing
- GenSci128 tablets
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced, Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with…
- Trial name
- SIE-3 (NCT07340658)
- Volunteers
- 300 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Solid Tumor, Adult
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
- Trial name
- NCT05866692
- Testing
- TY-2699a
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- TYK Medicines, Inc
Metastatic Breast Cancer
A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn about the effect of food on absorption of oral Paclitaxel when co- administered with Encequidar tablets in adult patients with tumours.
- Trial name
- NCT07580833
- Testing
- Oral Paclitaxel in combination with Encequidar tablet
- Volunteers
- 46 people
- Sponsor
- Health Hope Pharma
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
- Trial name
- NCT07062965
- Testing
- PF-07248144, Fulvestrant, Everolimus
- Where
- 433 sites in United States, Argentina and 29 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the…
- Trial name
- NCT06942767
- Testing
- QLS31905 for Injection, QL2107 Injection, Oxaliplatin Injection
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Ovarian Cancer
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients
This is a prospective, non-randomized, observational, clinical development study. Pierian Biosciences is utilizing ChemoINTEL and ImmunoINTEL assay measurements in human tumour cells from patients with advanced stage epithelial…
- Trial name
- ChemoINtel (NCT06844136)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Pierian Biosciences
Gastric Cancer, Oesophageal Carcinoma
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
This is a Phase 2, open-label, dose optimization/expansion study to assess the preliminary efficacy and safety of SAR445877 as a monotherapy for Chinese participants aged at least 18 years with advanced Gastric…
- Trial name
- NCT07692204
- Testing
- SAR445877
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sanofi
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Gastroesophageal Adenocarcinoma
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
TQB2102 for injection is a novel antibody-coupled drug (ADC) that enhances binding to tumor cell surface HER2 proteins by simultaneously targeting the two non-overlapping epitopes of the HER2 protein, Endothelial Cell Dysfunction…
- Trial name
- NCT06767800
- Testing
- TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy, TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy, TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy
- Where
- 39 sites in China
- Volunteers
- 204 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer, Advanced Solid Tumor
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06484816
- Testing
- TGRX-1942
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Melanoma
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in…
- Trial name
- NCT06008106
- Testing
- tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Advanced Malignant Solid Tumors
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150…
- Trial name
- NCT07566247
- Testing
- AK150
- Where
- 3 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Akeso
Melanoma, Non Small Cell Lung Cancer
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
- Trial name
- NCT05366478
- Testing
- Autologous tumor infiltrating lymphocytes (TILs)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Advanced Solid Tumors
Study of GS-2426 in Participants With Advanced Solid Tumors
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors.
- Trial name
- NCT07601243
- Testing
- GS-2426
- Where
- 6 sites in United States, Spain
- Volunteers
- 174 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.